DEVELOPING A SCALABLE ROUTE TO THE PROLINE CORE OF VOXILAPREVIR: AN ACTIVE INGREDIENT IN VOSEVI® FOR THE PAN-GENOTYPIC TREATMENT OF HEPATITIS C

Dunetz, J.; Chan, J.; Bonderoff, S.[1]; Bringley, D.; Cagulada, A.; Chan, L.; Duo, T.[1]; Gligoric–Trkulja, O.[1]; Huang, Z.; Keaton, K.; Phoenix, J.[1]; Ross, B.; Shah, N.; Shapiro, N.; Siler, D.; Tang, D.; Tiong, E.[1]; Williams, B.; Xu, D.; Yu, L.

Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404
[1]Gilead Alberta ULC, 1021 Hayter Road, Edmonton, Alberta, T6S 1A1, Canada
joshua.dunetz@gilead.com

Vosevi® is a fixed-dose combination of sofosbuvir, velpatasvir, and voxilaprevir for the pan-genotypic treatment of hepatitis C infection. Voxilaprevir has a complex structure highlighted by eight stereocenters, three cyclopropanes, and a proline core. Key developments of a process route will be discussed with focus on the assembly of the proline fragment.



voxilaprevir